Search Home / Profile / Linden Thomson: It’s no surprise first vaccines came from biotech rather than large-cap pharma Linden Thomson: It’s no surprise first vaccines came from biotech rather than large-cap pharma Axa Framlington Biotech fund manager on vaccine makers thriving even after Covid In November, markets received the first hopeful phase-III trial data from a Covid-19 vaccine candidate. Pfizer is the name most closely attached to the vaccine rolled out in the UK just before Christmas, but Axa Investment Managers biotechnology fund manager Linden Thomson says it should be known as the Biontech vaccine, given the German business was behind the development of the technology.